Kanglin Biotechnology Announces $20 Million Series A Financing to Advance the Development of Gene Therapies - Phase 1 study and Investigator Initiated Trial evaluating KL003 for patients with beta thalassemia demonstrated an encouraging efficacy signal and favorable safety profile – - Manufacturing costs...